Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 ROA % is 13.74% as of Dec. 2025, which is 25% below its 10-year median of 18.42. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 90.17% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Fujian Haixi Pharmaceuticals Co's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$195.6 Mil.
Fujian Haixi Pharmaceuticals Co's average Total Assets over the quarter that ended in Dec. 2025 was HK$1,423.5 Mil. Therefore, Fujian Haixi Pharmaceuticals Co's annualized ROA % for the quarter that ended in Dec. 2025 was 13.74%.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Fujian Haixi Pharmaceuticals Co ROA % Related Terms
Fujian Haixi Pharmaceuticals Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co ROA % Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
ROA %
16.39
23.70
20.45
13.74
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
ROA %
16.39
23.70
20.45
13.74
HKSE:02637 vs ZTS: ROA % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's ROA % distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a ROA % of 13.74% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is 25% below median its historical median of 18.42. Over the past decade, Fujian Haixi Pharmaceuticals Co's ROA % has ranged from 13.74 to 23.70. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #99 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 9.8%.
Is Fujian Haixi Pharmaceuticals Co's ROA % too high?
Fujian Haixi Pharmaceuticals Co's current ROA % of 13.74% is 25% below median its 10-year median of 18.42. Over the past 10 years, this metric has ranged from a low of 13.74 to a high of 23.70. The Drug Manufacturers industry median ROA % is 2.64. Fujian Haixi Pharmaceuticals Co's value of 13.74% is 420.5% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #99 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #99 out of 1007 companies for ROA %. This places Fujian Haixi Pharmaceuticals Co in the top 10% of its industry — outperforming the majority of peers. The industry median ROA % is 2.64. Fujian Haixi Pharmaceuticals Co's value of 13.74% is 420.5% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own ROA % has ranged from 13.74 to 23.70 over the past decade. While the company's 10-year median is 18.42 vs. the industry median of 2.64, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.64, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current ROA % of 13.74% is 420.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current ROA % is 13.74%, which is 25% below median its own 10-year median of 18.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current ROA % of 13.74%. The current ROA % is 13.74%, which is 25% below median its 10-year median of 18.42 and 420.5% above the Drug Manufacturers industry median of 2.64. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current ROA % is 13.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
